证券代码：603259 证券简称：药明康德 公告编号：临 2025-049 无锡药明康德新药开发股份有限公司 关于 2025 年中期利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每 10 股派发现金红利人民币 3.5000 元（含税）。 此次利润分配方案以实施权益分派股权登记日享有利润分配权（即扣减 回购专用证券账户中股份后）的总股本为基数，具体日期将在权益分派实施公告 中明确。 截至 2025 年 7 月 25 日，公司正在实施以集中竞价交易方式回购 A 股股 份方案。若自 2025 年 7 月 25 日起至实施权益分派股权登记日前公司享有利润分 配权（即扣减回购专用证券账户中股份后）的总股本发生变动的，按照每股分配 金额不变的原则进行分配，相应调整分配总额。 此次利润分配方案无需提交公司股东大会审议。 一、利润分配方案内容 变动的，按照每股分配金额不变的原则进行分配，相应调整分配总额。 此次利润分配方案无需提交公司股东大会审议。 二、公司履行的决策程序 （一）股东大会授权情况 公司于 ...

金十数据7月28日讯，药明康德公告，公司预计2025年持续经营业务收入重回双位数增长，增速从10- 15%上调至13-17%。公司预计全年整体收入从人民币415-430亿元上调至人民币425-435亿元。公司将聚 焦CRDMO核心业务，持续提高生产经营效率。报告期内，化学业务实现毛利人民币799,844.71万元， 毛利率较去年同期上升5.5%，主要得益于生产工艺持续优化以及临床后期和商业化项目增长带来的产 能效率不断提升。测试业务实现毛利人民币66,439.04万元，毛利率较去年同期下降12.1%，主要受市场 价格因素影响。生物学业务实现毛利人民币43,859.63万元，毛利率较去年同期下降1.0%。 药明康德：预计2025年持续经营业务收入重回双位数增长 ...

Core Viewpoint - WuXi AppTec expects its overall revenue for 2025 to be adjusted upwards from RMB 415-430 billion to RMB 425-435 billion, indicating a positive outlook for the company's financial performance [1] Revenue Growth - The company anticipates a return to double-digit growth in its continuing operations, with the growth rate revised from 10-15% to 13-17% for 2025 [1] Business Focus - WuXi AppTec will continue to focus on its CRDMO core business and aims to enhance production and operational efficiency [1] Shareholder Returns - In an effort to increase shareholder returns, the company has declared a special dividend of approximately RMB 1 billion, which was completed in May 2025 [1] - The board has approved a mid-year profit distribution plan for 2025, proposing a total cash dividend of around RMB 1 billion [1]

Group 1 - The core viewpoint of the article highlights WuXi AppTec's significant financial performance in the first half of 2025, with a revenue of 20.799 billion RMB, representing a year-on-year growth of 20.64% [1] - The net profit attributable to shareholders reached 8.561 billion RMB, showing a remarkable year-on-year increase of 101.92% [1] - The company plans to distribute a cash dividend of 3.5000 RMB per 10 shares to all shareholders, totaling a cash dividend payout of 1.003 billion RMB [1] Group 2 - The net cash flow from operating activities was reported at 7.431 billion RMB, reflecting a year-on-year growth of 49.63% [1]

药明康德（603259）公告，2025年上半年营业收入207.99亿元，同比增长20.64%。净利润85.61亿元， 同比增长101.92%。公司拟向全体股东每10股派发现金红利人民币3.5元(含税)，共计派发现金红利人民 币10.03亿元(含税)。 ...

公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 | 行股份（不包括庫存股 | | 庫存股份數目 | | | | | | 目 ...

Core Viewpoint - Morgan Stanley Capital International (MSCI) has awarded WuXi AppTec the highest "AAA" ESG rating, making it the first company in the A-share life and health industry to achieve this rating, reflecting its excellence in product safety, human capital development, and corporate governance [1] Group 1: ESG Rating and Performance - WuXi AppTec has maintained an "AA" rating for four consecutive years before achieving the "AAA" rating, indicating its ongoing commitment to ESG initiatives [1] - The MSCI ESG rating system ranges from "AAA" to "CCC," with "AAA" and "AA" representing leading companies in their sectors [1] Group 2: Quality Management and Information Security - WuXi AppTec has established a comprehensive Quality Management System (QMS), with over 80% of its main operational bases certified by international quality standards such as GMP, GLP, GCP, and ISO 9001 [2] - In 2024, the company underwent 802 quality audits from clients and regulatory bodies, achieving 100% compliance [2] - 89% of WuXi AppTec's main operational bases have ISO/IEC 27001 certification for information security management, with no significant incidents of information security breaches reported in 2024 [2] Group 3: Talent Development and Corporate Governance - WuXi AppTec emphasizes talent investment, with 54.71% of its global workforce being female and over 81% holding a bachelor's degree or higher [3] - The company provides an average of 58 hours of training per employee annually and ensures a safe working environment, with 89% of its main operational bases certified under ISO 45001 [3] - WuXi AppTec has integrated ESG into its operations through a robust governance structure, with an ESG committee responsible for setting strategies and monitoring implementation [3] Group 4: Broader ESG Engagement and Recognition - WuXi AppTec has been recognized in multiple ESG ratings, including being listed in the Dow Jones Sustainability Index for four consecutive years and receiving various leadership ratings from CDP and EcoVadis [4] - The company aims to deepen its sustainable practices, having its greenhouse gas reduction targets approved by SBTi and joining the Pharmaceutical Supply Chain Initiative (PSCI) and the United Nations Global Compact (UNGC) [4] - The recognition in ESG ratings underscores WuXi AppTec's credibility on the international stage and its potential for long-term value and sustainable growth [4]

智通财经7月27日电，麦格理将药明康德A股评级上调至跑赢大盘，目标价114元人民币，即上涨28%。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | | 購回股份(或其他證券)但沒有註銷 | | | | | | 2). | | 303,367 | 0.01 % | RMB | 65.96 | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...